Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), TransMedics Group (TMDX) and Opko Health (OPK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Align Tech (ALGN – Research Report), TransMedics Group (TMDX – Research Report) and Opko Health (OPK – Research Report).

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Align Tech (ALGN)

In a report released today, David Saxon from Needham maintained a Hold rating on Align Tech. The company’s shares closed last Wednesday at $131.91.

According to TipRanks.com, Saxon is a 1-star analyst with an average return of 0.0% and a 37.0% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Irhythm Technologies, and Alphatec Holdings. ;'>

Align Tech has an analyst consensus of Moderate Buy, with a price target consensus of $173.30, a 29.2% upside from current levels. In a report issued on October 16, UBS also maintained a Hold rating on the stock with a $155.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

TransMedics Group (TMDX)

Needham analyst Michael Matson reiterated a Buy rating on TransMedics Group today and set a price target of $148.00. The company’s shares closed last Wednesday at $134.32.

According to TipRanks.com, Matson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -2.3% and a 41.5% success rate. Matson covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Establishment Labs Holdings, and Zimmer Biomet Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for TransMedics Group with a $144.50 average price target, a 10.8% upside from current levels. In a report issued on October 23, William Blair also maintained a Buy rating on the stock.

Opko Health (OPK)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Opko Health today and set a price target of $3.00. The company’s shares closed last Wednesday at $1.43.

According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.7% and a 42.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, Bausch + Lomb Corporation, and Barinthus Biotherapeutics. ;'>

Opko Health has an analyst consensus of Strong Buy, with a price target consensus of $2.75.

Read More on ALGN:

Disclaimer & DisclosureReport an Issue

• Align Tech’s Strong International Growth and Innovative Products Drive Buy Rating
• Align Technology Reports Q3 2025 Financial Performance
• Closing Bell Movers: Meta sinks, Alphabet jumps after earnings
• Align Technology reportst Q3 adjusted EPS $2.61, consensus $2.41
• Align Technology sees Q4 revenue $1.025B-$1.045B, consensus $1.03B